PMA Data: High Approval Volume, Reduced Supplement Review Time For May
This article was originally published in The Gray Sheet
Executive Summary
FDA achieved highs in the volume of original PMAs and supplements approved in May, and lows in PMA supplement review times for approvals that month, according to analysis by “The Gray Sheet” of the agency’s most recent official monthly PMA listing. Exclusive graphical elements included.
You may also be interested in...
St. Jude To Acquire CardioMEMS As FDA Approves Heart Failure Monitor
FDA approved the CardioMEMS HF wireless heart-failure monitor, and St. Jude has exercised its option to buy the technology and its manufacturer. The approval is based on the results of the CHAMPION pivotal trial, which showed that patients monitored with the remote, implantable system needed fewer hospitalizations.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.